EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Smart Integration of Structural Biology and Medicinal Chemistry to Unlock Target‐Driven Drug Discovery

Matteo Rossi Sebastiano iD, Giulia Apprato iD, Serena Francisco iD, Giuseppe Ermondi iD, Giulia Caron iD

Medicinal Research Reviews · 2026-07 · 46 (4) · 921-944

DOI: 10.1002/med.70038 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medicinal Research Reviews, online erschienen am 16.03.2026. Verfasst von Matteo Rossi Sebastiano und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biotechnology and Health Sciences, CASSMedChem, University of Torino, Torino, Italy. Hauptthemen laut MEDLINE: Drug Discovery, Chemistry, Pharmaceutical, Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Università e della Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To enhance drug discovery efforts, medicinal chemists should evaluate, filter, and utilize relevant structural information about target proteins. Acquiring and interpreting protein structures is crucial for elucidating ligand‐receptor interactions and addressing ADME‐related considerations, making it an essential aspect of medicinal chemistry. Proteins exhibit diverse structural organizations, and their conformational variability poses challenges for drug design. Here we draw from our own experience how advances in structural biology have improved medicinal chemists’ access to 3D protein structures and dynamics, while stressing the need for model validation and refinement. To highlight the influence of structural biology on drug discovery, we present case studies. Structural insights into P‐glycoprotein have been crucial in addressing multidrug resistance, while the analysis of the oncoprotein β‐catenin provides valuable guidance for developing future therapeutic strategies based on innovative technology like targeted protein degradation. Finally, we report about multimeric complexes of proteins (Alsin and AP‐4) involved in rare HSPs and the contribution of protein–protein interaction analyses to discover mutation‐specific drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DiscoveryChemistry, PharmaceuticalProteinsHumansAnimalsProtein Conformationbeta CateninModels, Molecular

Stichwörter der Autor:innen

AP4M1AlsinP‐glycoproteinbeta‐cateninconformational variabilitydrug target 3D structureprotein structure predictionprotein structure refinement

Substanzen

beta CateninProteins

Autor:innen und Institutionen

  • Department of Molecular Biotechnology and Health Sciences, CASSMedChem, University of Torino, Torino, Italy.

ORCID-Profile: Matteo Rossi Sebastiano, Giulia Apprato, Serena Francisco, Giuseppe Ermondi, Giulia Caron

Förderung

  • Ministero dell'Università e della Ricerca

Zitieren

APA

Rossi Sebastiano, M., Apprato, G., Francisco, S., Ermondi, G., & Caron, G. (2026). Smart Integration of Structural Biology and Medicinal Chemistry to Unlock Target‐Driven Drug Discovery. Medicinal Research Reviews, 46(4), 921-944. https://doi.org/10.1002/med.70038

Vancouver

Rossi Sebastiano M, Apprato G, Francisco S, Ermondi G, Caron G. Smart Integration of Structural Biology and Medicinal Chemistry to Unlock Target‐Driven Drug Discovery. Medicinal Research Reviews. 2026;46(4):921-944. doi:10.1002/med.70038

BibTeX
@article{RossiSebastiano2026,
  author = {Rossi Sebastiano, Matteo and Apprato, Giulia and Francisco, Serena and Ermondi, Giuseppe and Caron, Giulia},
  title = {Smart Integration of Structural Biology and Medicinal Chemistry to Unlock Target‐Driven Drug Discovery},
  journal = {Medicinal Research Reviews},
  year = {2026},
  volume = {46},
  number = {4},
  pages = {921--944},
  doi = {10.1002/med.70038}
}
Kostenlos starten →